+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats



The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats



Diabetes and Vascular Disease Research 7(2): 138-144



We studied the effect of a synthetic GLP-1 receptor agonist, exenatide, a drug approved for the treatment of type 2 diabetes, on the recovery from vascular injury in Zucker (non-diabetic) fatty rats. Exenatide 5.0 microg/kg per day or saline was administered for seven days before, and 21 days after balloon catheter mediated carotid injury. A pair feeding experiment helped differentiate between the drug itself and the known effects of the drug on decreased food intake. Body weight and glucose (weekly), carotid artery I/M ratio, aortic protein eNOS and NFkappaB-p65 were measured. Body weight gain in exenatide rats was significantly lower (53+/-5 vs. 89+/-8 g) than controls. Blood glucose did not change significantly. The I/M ratio in the exenatide group was 0.2+/-0.1 vs. 0.9+/-0.1 in controls (p<0.05). The expression of aortic eNOS was unchanged in exenatide treated rats and a small decrease seen in NFkappaB-p65 expression was not statistically significant. We conclude that exenatide attenuates intimal hyperplasia following balloon catheter induced vascular injury independently of glucose regulation and food intake. Our findings provide additional support for cardiovascular benefits of exenatide, especially in obese and pre-diabetic patients. Further research is needed to elucidate the mechanism underlying these effects.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056509617

Download citation: RISBibTeXText

PMID: 20382777

DOI: 10.1177/1479164109360269


Related references

Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Molecular and Cellular Biochemistry 330(1-2): 1-8, 2009

Treatment of diabetic rats with insulin or a synthetic insulin receptor agonist peptide leads to divergent metabolic responses. Diabetes 64(3): 1057-1066, 2015

Acute insulin-sensitizing effect of an adenosine A1 receptor agonist in insulin resistant Zucker Fatty Rats. Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl. 1): R33, 2002

Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. Vascular Pharmacology 46(3): 188-194, 2006

Intimal hyperplasia following carotid endarterectomy in an insulin-resistant rat model. Metabolism, Clinical and Experimental 52(7): 834-839, 2003

GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. British Journal of Pharmacology 151(4): 450-456, 2007

Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochemical and Biophysical Research Communications 405(1): 79-84, 2011

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146(4): 2069-2076, 2005

Nitric oxide treatment reduces neo-intimal formation and modulates osteopontin expression in an ex-vivo human model of intimal hyperplasia. Cytokine 46(2): 228-235, 2009

A selective agonist for the somatostatin receptor subtype 2 inhibits intimal hyperplasia and improves neoendothelial histology following balloon catheter injury. FASEB Journal 10(3): A625, 1996

Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. Journal of Pharmacology and Experimental Therapeutics 328(1): 306-311, 2009

Exenatide modulates beta cell mass in insulin resistant obese fa/fa rats. Diabetologia 46(Suppl. 2): A29, 2003

Local shRNA modulation of phosphatidylinositol 3-kinase signaling pathway reduces intimal hyperplasia in vein grafts: experiment with rats. Zhonghua Yi Xue Za Zhi 87(24): 1713-1716, 2007

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovascular Diabetology 14: 10, 2015

Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism: Clinical and Experimental 54(5): 645-652, 2005